CVRx (CVRX) Stock Forecast & Price Target

CVRx Inc has demonstrated notable growth with an increase in the number of active implanting centers, reaching 240 by the end of the quarter, which signifies an expansion of its operational reach and potential market penetration. Despite a year-over-year increase in total operating expenses of approximately 8%, primarily due to rising selling, general, and administrative costs, the company's focus on growing its infrastructure suggests a strategic investment in future revenue generation. The emphasis on its proprietary Barostim technology positions CVRx favorably within the cardiovascular medical device sector, indicating a positive outlook for sustained revenue growth in a specialized market.

CVRx has reduced its FY25 revenue guidance to a range of $55.0 - $57.0 million, indicating a muted growth expectation of approximately 7-11% year-over-year, compared to a previous estimate that suggested slightly higher potential. Furthermore, the company has also lowered its 2026 revenue projection to $67.6 million from $74.1 million, reflecting expectations of a slower ramp-up in the U.S. market. Despite maintaining a gross margin of approximately 84% in Q2 2025, these downward revisions in revenue guidance highlight concerns regarding CVRx’s growth trajectory and market performance.